Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.
Adult
Aged
Aged, 80 and over
Anticholesteremic Agents
/ therapeutic use
Atorvastatin
/ therapeutic use
Cholesterol, LDL
/ blood
Dietary Supplements
Double-Blind Method
Dyslipidemias
/ drug therapy
Fatty Alcohols
/ administration & dosage
Female
Humans
Hypercholesterolemia
/ blood
Male
Middle Aged
Proprotein Convertase 9
/ blood
Vitamin K 2
/ administration & dosage
Vitamins
/ administration & dosage
LDL-C
Octacosanol
PCSK9
statins
supplementation
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
received:
31
01
2021
revised:
25
02
2021
accepted:
04
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Dietary supplementation with sugar cane derivates may modulate low-density lipoprotein cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purpose of this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) and vitamin K2 (45 µg), could restore the disrupted physiologic relation between LDL-C and serum PCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients on chronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS (
Identifiants
pubmed: 33802219
pii: nu13030903
doi: 10.3390/nu13030903
pmc: PMC8001635
pii:
doi:
Substances chimiques
Anticholesteremic Agents
0
Cholesterol, LDL
0
Fatty Alcohols
0
Vitamins
0
Vitamin K 2
11032-49-8
1-octacosanol
81I2215OVK
Atorvastatin
A0JWA85V8F
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Serbian Ministry of Education, Science, and Technological Development
ID : 451-03-68/2020-14/200161 and Project No III 41022
Références
J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43
pubmed: 19351729
Nutrients. 2014 Dec 01;6(12):5517-33
pubmed: 25470376
PLoS One. 2016 Mar 25;11(3):e0150785
pubmed: 27015087
J Lipid Res. 2010 Sep;51(9):2714-21
pubmed: 20525997
J Lipid Res. 2008 Feb;49(2):394-8
pubmed: 18033751
Pharmacol Res. 2017 Jun;120:157-169
pubmed: 28363723
Curr Opin Lipidol. 2014 Oct;25(5):387-93
pubmed: 25110901
J Biol Chem. 2009 Oct 16;284(42):28885-95
pubmed: 19687008
J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12
pubmed: 28826253
Eur Heart J. 2016 Feb 7;37(6):554-60
pubmed: 26508163
Curr Atheroscler Rep. 2016 Aug;18(8):46
pubmed: 27315084
Nutrients. 2020 May 16;12(5):
pubmed: 32429343
N Engl J Med. 2020 Apr 16;382(16):1507-1519
pubmed: 32187462
J Atheroscler Thromb. 2017 Sep 1;24(9):895-907
pubmed: 28804094
Am Heart J. 2006 Nov;152(5):982.e1-5
pubmed: 17070175
PLoS One. 2013;8(3):e60095
pubmed: 23544125
Phytother Res. 2008 Mar;22(3):318-22
pubmed: 18167048
Int J Cardiol. 2018 Jul 15;263:138-141
pubmed: 29754909
Am Heart J. 2001 Jun;141(6):949-56
pubmed: 11376309
Nat Genet. 2003 Jun;34(2):154-6
pubmed: 12730697
Evid Based Complement Alternat Med. 2014;2014:926087
pubmed: 25478000
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Circulation. 2016 Mar 29;133(13):1230-9
pubmed: 26896437
Heart. 2008 Oct;94(10):1331-2
pubmed: 18701534
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Atherosclerosis. 2002 Oct;164(2):347-54
pubmed: 12204807
Eur Heart J. 2016 Feb 7;37(6):546-53
pubmed: 26655339
Lipids. 2011 Oct;46(10):923-9
pubmed: 21739240
Mol Nutr Food Res. 2014 Aug;58(8):1620-35
pubmed: 24668744
Phytother Res. 2019 Apr;33(4):862-870
pubmed: 30632209
JAMA. 2006 May 17;295(19):2262-9
pubmed: 16705107
Br J Nutr. 2006 May;95(5):968-75
pubmed: 16611388
Mol Nutr Food Res. 2018 Jan;62(1):
pubmed: 28730734
Atherosclerosis. 2015 May;240(1):10-6
pubmed: 25744701
Mol Nutr Food Res. 2014 Nov;58(11):2133-45
pubmed: 25164566